Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination

Miñana, Juan Simó; Ganuza, M Gaztambide; Millán, Pilar Fernández; Fernández, Marina Peña

doi:10.1016/0264-410x(95)00176-2

Cited by 50 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is no consensus on the necessity of booster doses after neonatal immunization 12 . More than a decade ago it was recommended that 12-year-old children should receive a single booster dose 10 years after primary triple-dose vaccination because protection was estimated to last only 7.5 to 10.5 years 28 . Indeed, one study found that the geometric mean decay in the titre of antibody to HBsAg between the ages of 7 and 16 years in children who did not receive booster doses was 20.0% per year 47 .…”

Section: Discussionmentioning

confidence: 99%

Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China

Lao

Sahota

Law

et al. 2014

Bull. World Health Organ.

View full text Add to dashboard Cite

ObjectiveTo investigate the age-specific prevalence of hepatitis B virus (HBV) infection in young pregnant women in Hong Kong Special Administrative Region (SAR), China, and to determine whether an increase in prevalence occurs during adolescence.MethodsHBV prevalence was quantified using data from routine antenatal screening for hepatitis B surface antigen (HBsAg) in 10 808 women aged 25 years or younger born in Hong Kong SAR and managed at a single hospital between 1998 and 2011. The effect on prevalence of maternal age, parity and birth before or after HBV vaccine availability in 1984 was assessed, using Spearman’s correlation and multiple logistic regression analysis.FindingsOverall, 7.5% of women were HBsAg-positive. The prevalence ranged from 2.3% to 8.4% in those aged ≤ 16 and 23 years, respectively. Women born in or after 1984 and those younger than 18 years of age were less likely to be HBsAg-positive (odds ratio, OR: 0.679; 95% confidence interval, CI: 0.578–0.797) and (OR: 0.311; 95% CI: 0.160–0.604), respectively. For women born before 1984, there was no association between HBsAg carriage and being younger than 18 years of age (OR: 0.60; 95% CI: 0.262–1.370) Logistic regression analysis showed that the prevalence of HBsAg carriage was influenced more by the woman being 18 years old or older (adjusted OR, aOR: 2.80; 95% CI: 1.46–5.47) than being born before 1984 (aOR: 1.42; 95% CI: 1.21–1.67).ConclusionImmunity to HBV in young pregnant women who had been vaccinated as neonates decreased in late adolescence.

show abstract

Section: Discussionmentioning

confidence: 99%

Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China

Lao

Sahota

Law

et al. 2014

Bull. World Health Organ.

View full text Add to dashboard Cite

show abstract

“…Another study compared the two HBV vaccines, observing obesity as an independent risk factor (p< 0.01) for non-protective anti-HBs titers in Recombivax HB ™ -vaccinated health care workers in Minnesota [36]. Although the Engerix-B ™ -vaccinated cohort (n=169) lacked the same statistical power as the Recombivax HB ™ cohort (n=426) [36], it was confirmed through later studies [37, 38] that obesity was related to a significant decline (p< 0.01, p= 0.015, respectively) in Engerix-B ™ vaccine-induced anti-HBs titers. Since then, several studies have included analyses that continue to identify obesity as a risk factor for diminished or non-protective anti-HBs titers over time [39–42].…”

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 99%

The weight of obesity on the human immune response to vaccination

Painter

Ovsyannikova

Poland

2015

Vaccine

167

130

View full text Add to dashboard Cite

Despite the high success of protection against several infectious diseases through effective vaccines, some sub-populations have been observed to respond poorly to vaccines, putting them at increased risk for vaccine-preventable diseases. In particular, the limited data concerning the effect of obesity on vaccine immunogenicity and efficacy suggests that obesity is a factor that increases the likelihood of a poor vaccine-induced immune response. Obesity occurs through the deposition of excess lipids into adipose tissue through the production of adipocytes, and is defined as a body-mass index (BMI) ≥ 30 kg/m2. The immune system is adversely affected by obesity, and these “immune consequences” raise concern for the lack of vaccine-induced immunity in the obese patient requiring discussion of how this sub-population might be better protected.

show abstract

“…His group found that, high BMI was associated with a failure to develop detectable antibody response to Hepatitis B vaccine in health-care workers (19). Further, Simo Minnana et al reported lower antibody response in adolescents with high BMI when administered a three-dose regimen of recombinant hepatitis B vaccine (20). A randomized controlled trial compares triple-antigen vaccine vs standard single antigen vaccine administered in three doses over six months resulted in 71% and 95% protection rates in obese subjects when compared with lean subjects (91% & 99% respectively) (21).…”

Section: Introductionmentioning

confidence: 99%

Correlation between serum alanine aminotransferase activity and immunologic response and body mass index in obese patients with chronic hepatitis B virus infection

Al-Sharif

2017

Electron J Gen Med

View full text Add to dashboard Cite

Background & Objective:Chronic B viral hepatitis is a major health problem worldwide. Several studies have reported that obesity is important risk factors altered immune system response in individuals with no underlying causes of liver disease. This study was to examine the correlation between body mass index, serum alanine aminotransferase activity and immunologic response in obese hepatitis B Saudi patients. Subjects and Methods: One hundred fifty Saudi male patients with hepatitis B viral infection (HBV); their age ranged from 30 to 45 (38.64 ± 7.12) years. Patients were divided in to two equal groups according to their body mass index: Group (A): Included patients with HBV, their body mass index (BMI) was greater than 30 kg/m 2 (the obese group). Group (B): Included patients with HBV, their BMI between 20 and 24 kg/m 2 (the normal-weight group). Results: An elevation of serum alanine aminotransferase (ALT) activity was found to be associated with increased BMI, also we observed an elevation with regard to the normal weight group in the parameters of white blood cells, neutrophils, monocytes, CD3, CD4 and CD8 for group A. CD3, CD4 and CD8 correlated with BMI only as a total amount, as well as with all measured parameters of blood count. Conclusion: Obesity adversely affects the immunological response and rate of disease progression in HBeAg-negative chronic hepatitis B viral infection. Body weight control is important in the management of patients with chronic hepatitis B viral infection.

show abstract

Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination

Cited by 50 publications

References 16 publications

Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China

Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China

The weight of obesity on the human immune response to vaccination

Correlation between serum alanine aminotransferase activity and immunologic response and body mass index in obese patients with chronic hepatitis B virus infection

Contact Info

Product

Resources

About